AU2019328677A1 - Chimeric antigen receptors against multiple HLA-G isoforms - Google Patents

Chimeric antigen receptors against multiple HLA-G isoforms Download PDF

Info

Publication number
AU2019328677A1
AU2019328677A1 AU2019328677A AU2019328677A AU2019328677A1 AU 2019328677 A1 AU2019328677 A1 AU 2019328677A1 AU 2019328677 A AU2019328677 A AU 2019328677A AU 2019328677 A AU2019328677 A AU 2019328677A AU 2019328677 A1 AU2019328677 A1 AU 2019328677A1
Authority
AU
Australia
Prior art keywords
hla
car
cells
domain
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019328677A
Other languages
English (en)
Inventor
François ANNA
Julien Caumartin
Pierre Langlade Demoyen
Maria LOUSTAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invectys SAS
Original Assignee
Invectys SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys SAS filed Critical Invectys SAS
Publication of AU2019328677A1 publication Critical patent/AU2019328677A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019328677A 2018-08-31 2019-08-30 Chimeric antigen receptors against multiple HLA-G isoforms Abandoned AU2019328677A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18306153.0 2018-08-31
EP18306153 2018-08-31
EP19305809.6 2019-06-21
EP19305809 2019-06-21
PCT/EP2019/073257 WO2020043899A1 (en) 2018-08-31 2019-08-30 Chimeric antigen receptors against multiple hla-g isoforms

Publications (1)

Publication Number Publication Date
AU2019328677A1 true AU2019328677A1 (en) 2021-04-01

Family

ID=67766182

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019328677A Abandoned AU2019328677A1 (en) 2018-08-31 2019-08-30 Chimeric antigen receptors against multiple HLA-G isoforms

Country Status (12)

Country Link
US (5) US11117971B2 (enExample)
EP (1) EP3843778A1 (enExample)
JP (1) JP7394840B2 (enExample)
KR (1) KR20210112295A (enExample)
CN (1) CN112912105B (enExample)
AU (1) AU2019328677A1 (enExample)
BR (1) BR112021003757A2 (enExample)
IL (1) IL281097A (enExample)
MX (1) MX2021002316A (enExample)
SG (1) SG11202101849XA (enExample)
WO (1) WO2020043899A1 (enExample)
ZA (1) ZA202101358B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
BR112021003757A2 (pt) 2018-08-31 2021-05-25 Invectys SA receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
BR112021005868A2 (pt) 2018-09-27 2021-10-19 Tizona Therapeutics Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g
CN115996952A (zh) * 2020-06-11 2023-04-21 提圣纳医疗公司 对hla-g和另一种抗原具有结合特异性的双特异性免疫细胞接合子
WO2022129120A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
EP4079846A1 (en) * 2021-04-23 2022-10-26 SVAR Life Science AB Novel luciferases with improved properties
CA3221568A1 (en) * 2021-05-26 2022-12-01 Board Of Regents, The University Of Texas System Chimeric antigen receptor to target hla-g-positive cancers
TWI823402B (zh) * 2021-07-21 2023-11-21 長聖國際生技股份有限公司 多特異性單域抗體嵌合抗原受體及t細胞銜接體、核酸、其表達細胞、其用途以及治療癌症之醫藥組合物
US20240327492A1 (en) * 2021-07-29 2024-10-03 Nantcell, Inc. Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer
CN116218780A (zh) * 2021-12-03 2023-06-06 洪明奇 外泌体的生产及其用途
CN114605543B (zh) * 2021-12-17 2023-11-07 台州恩泽医疗中心(集团) 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
CN114380920B (zh) * 2021-12-17 2024-06-28 广州达安基因股份有限公司 人甲胎蛋白融合蛋白及其制备方法和应用
AU2023216270A1 (en) 2022-02-04 2024-08-15 Nkilt Therapeutics, Inc. Chimeric ilt receptor compositions and methods
CN118946585A (zh) * 2022-03-25 2024-11-12 怡诺安有限公司 抗hla-g嵌合抗原受体及其用途
CN115112900B (zh) * 2022-06-15 2024-08-16 四川大学华西医院 检测脂解激活脂蛋白受体的试剂和/或系统在制备恶性胸腔积液筛查产品中的用途
JP2025521577A (ja) * 2022-06-24 2025-07-10 エイチケー イノ．エヌ コーポレーション 免疫チェックポイント制御因子を発現する免疫細胞及びその用途
CN116284387B (zh) * 2022-07-15 2025-10-03 台州恩泽医疗中心(集团) 一种抗hla-g2及hla-g6分子的单克隆抗体及用途
JP2025539410A (ja) * 2022-11-28 2025-12-05 インベクティス，インコーポレイティド ヒト化抗ｈｌａ－ｇキメラ抗原受容体及びそれらの使用
CN116535500B (zh) * 2022-11-30 2024-03-22 西南大学 马铃薯x病毒单克隆抗体pvx-6及其应用
CN119569893B (zh) * 2023-09-06 2025-10-31 上海恩凯细胞技术有限公司 特异性靶向肿瘤的嵌合抗原受体细胞及其制备方法和应用
CN119569892A (zh) * 2023-09-06 2025-03-07 上海恩凯细胞技术有限公司 特异性靶向肿瘤非经典hla分子的嵌合抗原受体的应用
EP4793288A1 (en) * 2023-10-12 2026-08-19 Imbiologics Corp. Antibody specifically binding to hla-g, and use thereof
CN118420786B (zh) * 2024-06-12 2025-10-17 浙江大学医学院附属第一医院(浙江省第一医院) 一种靶向her2和hla-g的双特异性嵌合抗原受体及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
ES2185705T3 (es) 1994-05-02 2003-05-01 Bernd Groner Proteina bifuncional, preparacion y uso.
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
EP0819171A1 (en) 1995-04-07 1998-01-21 The Regents Of The University Of California Antibodies for the detection of hla-g
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
EP1967590A3 (en) 2001-03-13 2008-09-17 Novartis AG Lentiviral packaging constructs
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US20190119385A1 (en) * 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
CN107849102B (zh) * 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
CA3025681A1 (en) * 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
EP3515493A4 (en) 2016-09-23 2020-08-19 University of Southern California CHEMERICAL ANTIGEN RECEPTORS, COORESPONDENT COMPOSITIONS AND METHODS OF USE
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
BR112021003757A2 (pt) 2018-08-31 2021-05-25 Invectys SA receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
TWI694083B (zh) 2018-09-17 2020-05-21 中國醫藥大學附設醫院 嵌合抗原受體、核酸、嵌合抗原受體表達質體、表達嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
TWI717880B (zh) 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物

Also Published As

Publication number Publication date
US20260070988A1 (en) 2026-03-12
CN112912105B (zh) 2024-07-16
US11117971B2 (en) 2021-09-14
WO2020043899A1 (en) 2020-03-05
US20210040217A1 (en) 2021-02-11
US11325977B2 (en) 2022-05-10
US11505608B2 (en) 2022-11-22
JP2021534802A (ja) 2021-12-16
ZA202101358B (en) 2023-10-25
MX2021002316A (es) 2021-07-15
US20210403574A1 (en) 2021-12-30
US20230250175A1 (en) 2023-08-10
BR112021003757A2 (pt) 2021-05-25
US20220281981A1 (en) 2022-09-08
CN112912105A (zh) 2021-06-04
US12297275B2 (en) 2025-05-13
SG11202101849XA (en) 2021-03-30
IL281097A (en) 2021-04-29
JP7394840B2 (ja) 2023-12-08
KR20210112295A (ko) 2021-09-14
CA3110905A1 (en) 2020-03-05
EP3843778A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
US12297275B2 (en) Chimeric antigen receptors against multiple HLA-G isoforms
US20230303653A1 (en) Compositions and methods of chimeric autoantibody receptor t cells
US12600793B2 (en) Chimeric antigen receptors with MAGE-A4 specificity and uses thereof
JP2021532742A (ja) Ｎｅｆを含むｔ細胞及びその生成方法
CA3110905C (en) Chimeric antigen receptors against multiple hla-g isoforms
WO2025218739A1 (en) Polypeptide systems
EA051991B1 (ru) Химерные антигенные рецепторы к нескольким изоформам hla-g
KR20250139268A (ko) 인간화 항-hla-g 키메라 항원 수용체 및 이의 용도
WO2025021113A1 (zh) 用于治疗与cd20相关的疾病的融合蛋白
HK40074993A (en) Compositions and methods of chimeric autoantibody receptor t cells

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted